Special Issue "New Advances in the Treatment of Nonalcoholic Fatty Liver Disease"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 June 2018).
Interests: hepatology; gastroenterology; nutrition
Nonalcoholic fatty liver disease (NAFLD), is the most common liver disease worldwide. The estimated prevalence of NAFLD in the Western world, and in the urban areas of developing countries, is around 25% in the general population.
NAFLD is now considered the hepatic border of metabolic syndrome, supported by a high-calorie dietetic regimen, in the presence of a genetic profile characterized by predisposing polymorphisms. The “multi parallel hit” pathogenetic hypothesis of NAFLD, suggest that fat accumulation in the hepatocytes exposes the liver to oxidative stress with reactive oxygen species production, inflammation unbalance, cellular necrosis and, finally, fibrosis.
Several pharmacological treatments have been proposed in the last two decades for the treatment of NAFLD, but the reported results are inconclusive. In this way, international guidelines are been published on the management of patients with NAFLD and its related research agenda. However, many questions remain open. This Special Issue aims to become an overview about the currently available knowledge and recent findings regarding NAFLD therapies. I am honored to invite my distinguished colleagues to contribute with reviews and research articles that will stimulate the continuing efforts to better define the therapeutic management of NAFLD in clinical practice and to define the next five years of perspectives.Prof. Dr. Ludovico Abenavoli
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- nonalcoholic fatty liver disease
- new treatment
- insulin resistance
- liver fibrosis